INVESTIGATING THE POTENTIAL OF COMMD1 AS A NOVEL PROGNOSTIC MARKER OF SURVIVAL AND PREDICTOR OF NSAID RESPONSE IN PATIENTS

Stark, Lesley (Principal Investigator)

Status	Finished
Effective start/end date	1/06/12 → 6/10/14

Funding

UK central government bodies/local authorities, health and hospital authorities: £247,239.00

2 Article

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
Novo, S. M., Wedge, S. R. & Stark, L. A., 20 Sep 2017, In: Scientific Reports.
Research output: Contribution to journal › Article › peer-review

Open Access
File
p300-mediated acetylation of COMMD1 regulates its stability, and the ubiquitylation and nucleolar translocation of the RelA NF-kappa B subunit
O'Hara, A., Simpson, J., Morin, P., Loveridge, C. J., Williams, A. C., Novo, S. M. & Stark, L. A., 1 Sep 2014, In: Journal of Cell Science. 127, 17, p. 3659-3665 7 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File